A Pyrimidine-Based Tubulin Inhibitor Shows Potent Anti-Glioblastoma Activity In Vitro and In Vivo.

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Glioblastoma (GBM) is a highly aggressive brain tumor with limited treatment options.
• Tubulin is a critical target for cancer therapy due to its role in cell division and signaling.
• Novel small-molecule tubulin inhibitors are being developed to combat treatment-resistant cancers like GBM.

Purpose of the Study:

• To synthesize and evaluate novel pyrimidine-containing dihydroquinoxalinone analogs as potential glioblastoma therapeutics.
• To identify and characterize the most potent compound for further preclinical development.

Main Methods:

• Synthesis of a focused library of pyrimidine-based analogs.
• Cytotoxicity assessment using the Sulforhodamine B assay in GBM cell lines.
• In vitro evaluation of lead compound 8c for cell growth inhibition and apoptosis induction.
• In vivo efficacy testing of compound 8c in GBM xenograft mouse models.

Main Results:

• Several synthesized compounds exhibited nanomolar IC50 values, surpassing the efficacy of temozolomide (TMZ).
• Compound 8c demonstrated potent dose-dependent inhibition of GBM cell viability and induced complete growth arrest.
• Compound 8c effectively triggered apoptosis in GBM cells and significantly inhibited tumor growth by 66% in vivo.
• TMZ failed to induce apoptosis at nanomolar concentrations, highlighting compound 8c's superior mechanism.

Conclusions:

• Compound 8c is a potent tubulin inhibitor with significant anti-GBM activity in vitro and in vivo.
• The identified compound warrants further preclinical investigation as a potential novel therapy for glioblastoma.